Karyopharm TherapeuticsKPTI
13F holders, Q2 2025 (June 30)1holders −1
0new positions
1sold out
$4.31avg. 13F price*
At the end of Q2 2025, 1 institutions reported holding Karyopharm Therapeutics Inc. (KPTI) in their 13F filings, down 1 from Q1 2025. 0 opened new positions and 1 sold out. The largest holder was Birchview Capital, LP ($121K).
- Company
- Karyopharm Therapeutics Inc.
- CUSIP
- 48576U106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $1.2M |
All 13F filers, Q1 2025 → Q2 2025: 324,032 shares sold, net −324,032 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Birchview Capital, LP | 0.12% | No change | 27,985 | $121K |
"% of holder's portfolio" is KPTI's weight in each manager's 13F, not the share of Karyopharm Therapeutics Inc. the manager owns.